Blood-Based Biomarker Testing for Alzheimer Disease in US Clinical Practice Blood-based biomarker (BBM) tests have generated considerable interest as potentially less invasive, costly, and burdensome approaches to detecting Alzheimer disease (AD) pathology than cerebrospinal fluid (CSF) testing or positron emission tomography (PET).1 Several BBM tests measuring phosphorylated tau (p-tau) and amyloid-β (Aβ) are now commercially available as laboratory-developed tests.2 Since 2025, 4 plasma BBM...
Joseph Ross
Get in touch with Joseph
Contact Joseph, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack